The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen‐deprivation therapy
Abstract
BACKGROUND: Prostate carcinoma (PCa) is one of the most common malignancies in men. Androgen‐deprivation therapy (ADT) is used frequently in the treatment of recurrent and metastatic PCa, rendering these men hypogonadal. Because male hypogonadism is associated with an unfavorable metabolic profile, and men with PCa have high cardiovascular mortality, the authors evaluated the effects of long‐term ADT on fasting glucose levels, insulin levels, and insulin resistance. METHODS: To evaluate the long‐term effects of ADT on fasting glucose and insulin resistance in men with PCa who received ADT and to determine whether these metabolic alterations are a result of hypogonadism, the authors conducted a cross‐sectional study at a university‐based research institution in the United States. In total, 53 men were evaluated, including 18 men with PCa who received ADT for at least 12 months prior to the onset of the study (the ADT group), 17 age‐matched men with nonmetastatic PCa who had undergone prostatectomy and/or received radiotherapy and who were not receiving ADT (the non‐ADT group), and 18 age‐matched controls (the control group). None of the men had a known history of diabetes mellitus. RESULTS: The mean age was similar in all 3 groups (P = 0.33). Serum total testosterone levels (P < 0.0001) and free testosterone levels (P < 0.0001) were significantly lower in the ADT group compared with the other groups. Men in the ADT group had a higher BMI compared with the other groups (overall P = 0.005). After adjustment for age and BMI, men in the ADT group had significantly higher fasting levels of the following parameters: 1) Glucose levels were 131.0 ± 7.43 mg/dL in the ADT group compared with 103.0 ± 7.42 mg/dL in the non‐ADT group (P = 0.01) and 99.0 ± 7.58 mg/dL in the control group (P < 0.01). 2) Insulin levels were 45.0 ± 7.25 uU/mL in the ADT group compared with 24.0 ± 7.24 uU/mL in the non‐ADT group (P = 0.05) and 19.0 ± 7.39 uU/mL in the control group (P = 0.02). 3) Leptin levels were 25.0 ± 2.57 ng/mL in the ADT group compared with 12.0 ± 2.56 ng/mL in the non‐ADT group (P < 0.01) and 6.0 ± 2.62 ng/mL in the control group (P < 0.01). 4) The homeostatic model assessment for insulin resistance (HOMA IR) = 17.0 ± 2.78 in the ADT group compared with HOMA IR = 6.0 ± 2.77 in the non‐ADT group (P < 0.01) and HOMA IR = 5.0 ± 2.83 in the control group (P = 0.01). There was a significant negative correlation between total and free testosterone levels with fasting glucose, insulin, leptin, and HOMA IR. CONCLUSIONS: The current data suggested that men with PCa who are receiving long‐term ADT are at risk for developing insulin resistance and hyperglycemia, thus leading to their increased risk of cardiovascular disease. This adverse metabolic profile developed independent of age and BMI and appeared to be a direct result of androgen deprivation. Cancer 2006. © 2005 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Landis, S. H., Murray, T., Bolden, S., & Wingo, P. A. (1999) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.49.1.8 · Cited by 3,068
Bolla, M., Gonzalez, D., Warde, P., Dubois, J. B., Mirimanoff, R.-O., Storme, G., Bernier, J., Kuten, A., Sternberg, C., Gil, T., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707313370502 · Cited by 1,548
Biological Action of Leptin as an Angiogenic Factor
Sierra-Honigmann, M. R., Nath, A. K., Murakami, C., Garcı́a-Cardeña, G., Papapetropoulos, A., Sessa, W. C., Madge, L. A., Schechner, J. S., Schwabb, M. B., Polverini, P. J., et al. (1998) · Science · doi:10.1126/science.281.5383.1683 · Cited by 1,371
Messing, E. M., Manola, J., Sarosdy, M., Wilding, G., Crawford, E. D., & Trump, D. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912093412401 · Cited by 1,191
Laaksonen, D. E., Niskanen, L., Punnonen, K., Nyyssönen, K., Tuomainen, T.-P., Valkonen, V.-P., Salonen, R., & Salonen, J. T. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1036 · Cited by 920
Divergent Signaling Capacities of the Long and Short Isoforms of the Leptin Receptor
Bjørbæk, C., Uotani, S., da Silva, B., & Flier, J. S. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.51.32686 · Cited by 890
Lillioja, S., Young, A. A., Culter, C. L., Ivy, J. L., Abbott, W. G., Zawadzki, J. K., Yki-Järvinen, H., Christin, L., Secomb, T. W., & Bogardus, C. (1987) · Journal of Clinical Investigation · doi:10.1172/jci113088 · Cited by 782
Malkin, C. J., Pugh, P. J., Jones, R. D., Kapoor, D., Channer, K. S., & Jones, T. H. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031069 · Cited by 731
Stellato, R. K., Feldman, H. A., Hamdy, O., Horton, E. S., & McKinlay, J. B. (2000) · Diabetes Care · doi:10.2337/diacare.23.4.490 · Cited by 618
Oh, J.-Y., Barrett-Connor, E., Wedick, N. M., & Wingard, D. L. (2002) · Diabetes Care · doi:10.2337/diacare.25.1.55 · Cited by 594 · cited 1×
“Epidemiological studies have shown that men with low testosterone levels are more prone to develop diabetes mellitus than their eugonadal counterparts.(5,6) This is supported by interventional studies showing that testosterone replacement in hypogonadal, obese men results in an improvement in insulin sensitivity.”
BackgroundMechanisms of Insulin Resistance in Aging
Fink, R. I., Kolterman, O. G., Griffin, J., & Olefsky, J. M. (1983) · Journal of Clinical Investigation · doi:10.1172/jci110908 · Cited by 555
The effects of testosterone treatment on body composition and metabolism in middle-aged obese men.
Mårin, P., Holmäng, S., Jönsson, L., Sjöström, L., Kvist, H., Holm, G., Lindstedt, G., & Björntorp, P. A. (1992) · PubMed · Cited by 553
Mora, L. B., Buettner, R., Seigne, J. D., Diaz, J. I., Ahmad, N., Garcia, R., Bowman, T. L., Falcone, R., Fairclough, R., Cantor, A. B., et al. (2002) · PubMed · Cited by 533
Sinha-Hikim, I., Artaza, J., Woodhouse, L., Gonzalez-Cadavid, N., Singh, A. B., Lee, M. I., Storer, T. W., Casaburi, R., Shen, R., & Bhasin, S. (2002) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00502.2001 · Cited by 464
Smith, J. C., Bennett, S., Evans, L. M., Kynaston, H. G., Parmar, M., Mason, M. D., Cockcroft, J. R., Scanlon, M. F., & Davies, J. S. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.9.7851 · Cited by 458
Effects of Testosterone on Coronary Vasomotor Regulation in Men With Coronary Heart Disease
Webb, C. M., McNeill, J. G., Hayward, C. S., de Zeigler, D., & Collins, P. (1999) · Circulation · doi:10.1161/01.cir.100.16.1690 · Cited by 451
The association of hypotestosteronemia with coronary artery disease in men.
Phillips, G. B., Pinkernell, B. H., & Jing, T. Y. (1994) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.14.5.701 · Cited by 399
Acute Anti-Ischemic Effect of Testosterone in Men With Coronary Artery Disease
Rosano, G. M. C., Leonardo, F., Pagnotta, P., Pelliccia, F., Panina, G., Cerquetani, E., della Monica, P. L., Bonfigli, B., Volpe, M., & Chierchia, S. L. (1999) · Circulation · doi:10.1161/01.cir.99.13.1666 · Cited by 367
Long‐term effects of androgen deprivation therapy in prostate cancer patients
Basaria, S., Lieb, J., Tang, A. M., DeWeese, T., Carducci, M., Eisenberger, M., & Dobs, A. S. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.01551.x · Cited by 359
Self-citationHaffner, S. M., Shaten, J., Stem, M. P., Smith, G. D., Kuller, L., & MRFIT Research Group (1996) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a008832 · Cited by 320
Insulin Resistance, Body Fat Distribution, and Sex Hormones in Men
Haffner, S. M., Karhapää, P., Mykkänen, L., & Laakso, M. (1994) · Diabetes · doi:10.2337/diab.43.2.212 · Cited by 307
Prostate Cancer Risk and Serum Levels of Insulin and Leptin: a Population-Based Study
Hsing, A. W., Chua, S., Gao, Y.-T., Gentzschein, E., Chang, L., Deng, J., & Stanczyk, F. Z. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.10.783 · Cited by 298
DOCKERY, F., BULPITT, C. J., AGARWAL, S., DONALDSON, M., & RAJKUMAR, C. (2003) · Clinical Science · doi:10.1042/cs1040195 · Cited by 294
Insulin Resistance and Prostate Cancer Risk
Hsing, A. W., Gao, Y.-T., Chua, S., Deng, J., & Stanczyk, F. Z. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.1.67 · Cited by 242
Inverse Correlation between Serum Testosterone and Leptin in Men1
Luukkaa, V., Pesonen, U., Huhtaniemi, I., Lehtonen, A., Tilvis, R., Tuomilehto, J., Koulu, M., & Huupponen, R. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.9.5134 · Cited by 230
Haffner, S. M., Valdez, R. A., Mykkänen, L., Stern, M. P., & Katz, M. S. (1994) · Metabolism · doi:10.1016/0026-0495(94)90202-x · Cited by 226
Simon, D. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.2.682 · Cited by 220
Leptin Is Associated with Increased Prostate Cancer Risk: A Nested Case-Referent Study1
Stattin, P., Söderberg, S., Hallmans, G., Bylund, A., Kaaks, R., Stenman, U.-H., Bergh, A., & Olsson, T. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.3.7328 · Cited by 196
Prostate Cancer Cell-Adipocyte Interaction
Onuma, M., Bub, J. D., Rummel, T. L., & Iwamoto, Y. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304984200 · Cited by 189
The effects of testosterone on insulin sensitivity in male rats
HOLMÄNG, A., & BJÖRNTORP, P. (1992) · Acta Physiologica Scandinavica · doi:10.1111/j.1748-1716.1992.tb09452.x · Cited by 188
Inverse Correlation between Serum Testosterone and Leptin in Men
Luukkaa, V. (1998) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.9.3243 · Cited by 159
Leptin Is Associated with Increased Prostate Cancer Risk: A Nested Case-Referent Study
Stattin, P. E. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.3.1341 · Cited by 142
Cause of death in men diagnosed with prostate carcinoma
Satariano, W. A., Ragland, K. E., & Eeden, S. K. V. D. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980915)83:6<1180::aid-cncr18>3.0.co;2-1 · Cited by 133
Baumgartner, R. N., Waters, D. L., Morley, J. E., Patrick, P., Montoya, G. D., & Garry, P. J. (1999) · Metabolism · doi:10.1016/s0026-0495(99)90089-6 · Cited by 118
Prostate cancer: another aspect of the insulin‐resistance syndrome?
Barnard, R. J., Aronson, W. J., Tymchuk, C. N., & Ngo, T. H. (2002) · Obesity Reviews · doi:10.1046/j.1467-789x.2002.00081.x · Cited by 115
Prostatic Hyperplasia: An Unknown Feature of Acromegaly
Colao, A., Marzullo, P., Ferone, D., Spiezia, S., Cerbone, G., Marino, V. D., Sarno, A. D., Merola, B., & Lombardi, G. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.3.4645 · Cited by 115
CHANGING PATTERNS IN COMPETING CAUSES OF DEATH IN MEN WITH PROSTATE CANCER: A POPULATION BASED STUDY
Lu‐Yao, G. L., Stukel, T. A., & Yao, S. (2004) · The Journal of Urology · doi:10.1097/01.ju.0000127740.96006.1a · Cited by 110
The android woman – a risky condition
Björntorp, P. A. (1996) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1996.364690000.x · Cited by 102
The role of angiogenesis in prostate and other urologic cancers: a review.
Izawa, J. I., & Dinney, C. P. (2001) · Europe PMC (PubMed Central) · Cited by 53
Ribeiro, R. J. T., Lopes, C., & Medeiros, R. (2004) · European Journal of Cancer Prevention · doi:10.1097/00008469-200410000-00002 · Cited by 45
Cited by
Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them
Nguyen, P. L., Alibhai, S. M. H., Basaria, S., D’Amico, A. V., Kantoff, P. W., Keating, N. L., Penson, D. F., Rosario, D. J., Tombal, B., & Smith, M. R. (2015) · European Urology · doi:10.1016/j.eururo.2014.07.010 · Cited by 831
Self-citationMetabolic Syndrome in Men With Prostate Cancer Undergoing Long-Term Androgen-Deprivation Therapy
Braga-Basaria, M., Dobs, A. S., Muller, D. C., Carducci, M. A., John, M., Egan, J., & Basaria, S. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9741 · Cited by 585
Self-citationLow testosterone levels are common and associated with insulin resistance in men with diabetes
Grossmann, M., Thomas, M. C., Panagiotopoulos, S., Sharpe, K., MacIsaac, R. J., Clarke, S., Zajac, J. D., & Jerums, G. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2177 · Cited by 468
Ma, J., Li, H., Giovannucci, E., Mucci, L., Qiu, W., Nguyen, P. L., Gaziano, J. M., Pollak, M., & Stampfer, M. J. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70235-3 · Cited by 421
Gender differences in glucose homeostasis and diabetes
Mauvais-Jarvis, F. (2018) · Physiology & Behavior · doi:10.1016/j.physbeh.2017.08.016 · Cited by 377
Metadata
- Authors
- Basaria, S., Muller, D. C., Carducci, M. A., Egan, J., & Dobs, A. S.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2005-12-30
- Volume
- 106
- Issue
- 3
- Pages
- 581-588
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2020438145
- Cited by
- 394
- References
- 41
- FWCI
- 10.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.